Phospho-WWOX (Tyr33) Antibody

What is WWOX and why is Tyr33 phosphorylation significant in research?

WWOX (WW domain-containing oxidoreductase) is a tumor suppressor protein that plays critical roles in various cellular processes including apoptosis, cell growth, and DNA repair. Phosphorylation of WWOX at Tyrosine 33 (Tyr33) is a key post-translational modification that significantly alters its function and binding capabilities.

Tyr33 phosphorylation occurs within the first WW domain of WWOX, which is crucial for protein-protein interactions . When WWOX is phosphorylated at Tyr33 (pY33-WWOX), it acquires enhanced capability to bind a broad spectrum of proteins, including p53, c-Jun, and other transcription factors . This phosphorylation is typically mediated by tyrosine kinase Src .

The significance of Tyr33 phosphorylation lies in its role as a molecular switch that determines WWOX function:

• In normal tissues: Activated WWOX with Tyr33 phosphorylation is present in physiological conditions

• Under stress conditions: Excessive pY33-WWOX can trigger apoptotic pathways

• In disease progression: The transition from pY33-WWOX to pS14-WWOX (phosphorylation at Serine 14) appears to be associated with cancer progression and neurodegeneration

What are the primary applications of Phospho-WWOX (Tyr33) antibodies in research?

Phospho-WWOX (Tyr33) antibodies are versatile research tools with multiple applications:

These antibodies specifically detect endogenous levels of WWOX protein only when phosphorylated at Tyr33, making them invaluable for studying WWOX activation status in various experimental conditions .

How should researchers optimize storage and handling of Phospho-WWOX (Tyr33) antibodies?

For optimal performance and extended shelf life of Phospho-WWOX (Tyr33) antibodies, researchers should implement the following best practices:

• Storage temperature: Store at -20°C for up to 1 year from the date of receipt

• Aliquoting: Upon receiving the antibody, prepare small aliquots to avoid repeated freeze/thaw cycles that can damage antibody integrity

• Buffer conditions: Most commercial antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide

• Working solutions: Dilute only the amount needed for immediate use

• Thawing procedure: Allow frozen antibody to thaw completely at 4°C before use

When handling the antibody for experiments, researchers should:

• Maintain sterile technique to prevent contamination

• Optimize antibody concentration for each application and cell/tissue type

• Include appropriate positive and negative controls in each experiment

• Document lot numbers and validate new lots against previous results

How can researchers differentiate between Tyr33 and Ser14 phosphorylated forms of WWOX?

Distinguishing between different phosphorylated forms of WWOX is critical for understanding its functional transitions in disease pathology. Current research indicates that pY33-WWOX and pS14-WWOX have distinct and sometimes opposing functions .

Methodological approach to differentiate these phosphorylated forms:

• Specific antibodies: Use antibodies that recognize specific phosphorylation sites:

  • Anti-phospho-WWOX (Tyr33) antibodies specifically detect WWOX phosphorylated at Tyr33

  • Anti-phospho-WWOX (Ser14) antibodies detect the serine-phosphorylated form

• Phosphatase treatment controls: Include samples treated with lambda phosphatase to confirm specificity for phosphorylated epitopes

• Phosphomimetic mutants: For functional studies, create WWOX mutants:

  • Y33E or Y33D (mimics phosphorylation at Tyr33)

  • Y33F (prevents phosphorylation at Tyr33)

  • S14D or S14E (mimics phosphorylation at Ser14)

  • S14A (prevents phosphorylation at Ser14)

• 2D gel electrophoresis: Separate different phosphorylated forms based on charge differences

• Temporal analysis: Monitor the pY33-to-pS14 transition during disease progression:

  • Early cancer stages show increased pY33-WWOX

  • Advanced cancer and neurodegeneration show increased pS14-WWOX

In experimental design, researchers should consider that "pS14-WWOX can be regarded as a marker of disease progression" while pY33-WWOX is associated with tumor suppression and normal physiology .

What signaling pathways are regulated by Tyr33-phosphorylated WWOX?

Tyr33-phosphorylated WWOX (pY33-WWOX) participates in multiple signaling cascades that regulate cell survival, apoptosis, and stress responses:

• WWOX/p53 pathway:

  • UV irradiation activates cytosolic WWOX via Tyr33 phosphorylation

  • pY33-WWOX binds Ser46-phosphorylated p53

  • Both proteins relocate to mitochondria or nuclei to induce apoptosis

  • Estrogen initiates binding of pY33-WWOX with pS15-p53

• JNK and MAPK interactions:

  • pY33-WWOX physically interacts with JNK1 and ERK

  • This interaction blocks enzyme-mediated tau hyperphosphorylation

  • JNK can suppress WWOX-induced apoptosis by binding and functionally blocking pY33-WWOX

• IκBα/WWOX/ERK signaling:

  • Calcium ionophore and phorbol ester force T lymphoblastic leukemia differentiation through this pathway

  • This involves WWOX phosphorylation at Ser14

• TGF-β signaling:

  • pY33-WWOX interacts with SMAD proteins in the TGF-β pathway

  • During traumatic brain injury, activation of Hyal-2/WWOX/Smad4 signaling causes neuronal death

  • TGF-β1 may utilize Hyal-2/WWOX/Smad4 signaling to enhance cell survival or death

• Wnt signaling inhibition:

  • WWOX inhibits Wnt signaling by sequestering DVL2 in the cytoplasm

  • This function may be regulated by phosphorylation status

These pathways highlight the complex role of pY33-WWOX as both a tumor suppressor and regulator of cell fate decisions.

What are the validated experimental models for studying Phospho-WWOX (Tyr33) functions?

Researchers have established several experimental models to study Phospho-WWOX (Tyr33) functions across different biological contexts:

• Cell culture models:

  • T lymphoblastic leukemia cells: For studying differentiation involving IκBα/WWOX/ERK signaling

  • Neuroblastoma cells: For studying aggregation of proteins related to neurodegeneration

  • Cancer cell lines: For investigating WWOX's role in cancer progression

• Animal models:

  • Hairless mice exposed to UVB: Model for skin squamous cell carcinoma showing WWOX upregulation and Tyr33 phosphorylation during acute phase

  • Traumatic brain injury in rats: Demonstrates Hyal-2/WWOX signaling in neuronal death

  • Sciatic nerve dissection in rats: Shows pY33-WWOX accumulation in neurons during acute injury

  • LPS-induced sepsis model in mice: Reveals reduced Tyr33 phosphorylated WWOX in cerebral cortex associated with sickness behavior

• Genetic models:

  • WWOX knockout mice: Develop osteosarcoma (especially in p53/WWOX double knockout)

  • WWOX-deficient metastatic cancer cells: Show altered behavior including dodging WWOX-positive cells

• Acute stress induction models:

  • UV irradiation: Activates WWOX via Tyr33 phosphorylation

  • MPP+ (1-methyl-4-phenylpyridinium) neurotoxin: Induces pY33-WWOX upregulation in rat neurons

  • Constant light exposure: Causes retinal neural degeneration involving WWOX activation

Key experimental considerations include:

• Timing of analysis (acute vs. chronic effects)

• Cell/tissue specificity of WWOX functions

• Microenvironmental factors affecting WWOX phosphorylation

What technical challenges exist in detecting endogenous Phospho-WWOX (Tyr33) in experimental samples?

Detecting endogenous Phospho-WWOX (Tyr33) presents several technical challenges that researchers should address:

• Low abundance issue:

  • Endogenous WWOX expression varies by tissue type

  • Phosphorylated forms may represent only a small fraction of total WWOX

  • Solution: Use enrichment techniques like immunoprecipitation before detection

• Phosphorylation transience:

  • Tyr33 phosphorylation may be rapidly dynamic

  • Phosphatases can quickly dephosphorylate during sample preparation

  • Solution: Include phosphatase inhibitors in all buffers and maintain samples at 4°C

• Tissue-specific expression patterns:

  • WWOX expression and phosphorylation status varies significantly across tissues

  • Different cell types within the same tissue may have varying levels

  • Solution: Use positive control tissues known to express pY33-WWOX (e.g., brain hippocampus)

• Subcellular localization changes:

  • pY33-WWOX can translocate between cytoplasm, nucleus, mitochondria, and other organelles

  • Solution: Perform subcellular fractionation or use confocal microscopy with co-localization markers

• Antibody specificity concerns:

  • Phospho-specific antibodies may show cross-reactivity with similar epitopes

  • Solution: Validate specificity using:

    • Phosphatase-treated samples as negative controls

    • WWOX-knockout cells/tissues as controls

    • Peptide competition assays with phosphorylated and non-phosphorylated peptides

• Fixation sensitivity:

  • Phospho-epitopes may be sensitive to certain fixatives

  • Solution: Optimize fixation protocols (paraformaldehyde often preserves phospho-epitopes better than methanol)

• Signal amplification needs:

  • Weak signals may require amplification methods

  • Solution: Consider tyramide signal amplification (TSA) or polymer detection systems

How does the balance between Tyr33 and Ser14 phosphorylation influence disease pathology?

The transition between different WWOX phosphorylation states appears to be a critical mechanism in disease pathogenesis:

• Cancer progression dynamics:

  • Early cancer stages: WWOX is significantly upregulated and activated with Tyr33 phosphorylation

  • pY33-WWOX struggles to block cancer progression and eliminate damaged cells by apoptosis

  • Later stages: WWOX protein is reduced or absent, enhancing cancer cell growth and metastasis

  • Transition from pY33-WWOX to pS14-WWOX appears to mark the shift from anti-cancer to pro-cancer roles

• Neurodegenerative diseases:

  • pY33-WWOX normally blocks tau hyperphosphorylation by binding enzymes like GSK-3β

  • pS14-WWOX is upregulated in brain regions affected by Alzheimer's disease

  • Reduction of pS14-WWOX by Zfra peptide mitigates Alzheimer's disease progression

  • Reduced Tyr33 phosphorylated WWOX in sepsis is associated with sickness behavior in mouse models

• Molecular mechanisms mediating the transition:

  • Oxidative stress conditions can affect the phosphorylation balance

  • WWOX via its C-terminal SDR domain controls ROS generation

  • Warburg metabolism (increased glycolysis) correlates with downregulated WWOX expression

  • Hormonal factors: 17β-estradiol (E2) binds WWOX at an NSYK motif and affects its function

• Clinical implications:

  • pS14-WWOX can be regarded as a marker of disease progression

  • The pY33-to-pS14 transition potentially represents a targetable intervention point

  • Therapies aimed at maintaining pY33-WWOX or preventing pS14-WWOX formation might slow disease progression

This dynamic phosphorylation balance underscores the complex role of WWOX as both a tumor suppressor and potential disease modifier depending on its phosphorylation state.

What validation steps should researchers take when using Phospho-WWOX (Tyr33) antibodies?

Proper validation is essential for generating reliable data with Phospho-WWOX (Tyr33) antibodies. Researchers should implement the following comprehensive validation strategy:

• Epitope verification:

  • Review the immunogen sequence used to generate the antibody

  • Most commercial Phospho-WWOX (Tyr33) antibodies use synthetic phosphopeptides derived from the region surrounding Tyr33

  • Example immunogen sequence: W-V-Y(P)-Y-A or amino acids 18-67 of human WWOX

• Specificity controls:

  • Phosphatase treatment: Treat positive samples with lambda phosphatase to confirm loss of signal

  • Peptide competition: Pre-incubate antibody with phosphorylated and non-phosphorylated peptides

  • WWOX knockdown/knockout: Use siRNA or CRISPR to create negative controls

  • Phosphomimetic mutants: Compare detection of wild-type vs. Y33F (non-phosphorylatable) WWOX

• Cross-reactivity assessment:

  • Test on multiple species if claiming cross-reactivity (e.g., human and mouse)

  • Evaluate potential cross-reactivity with related proteins containing similar phospho-motifs

  • Perform immunoprecipitation followed by mass spectrometry to identify all bound proteins

• Application-specific validation:

  • Western blot: Verify single band of correct molecular weight (~46 kDa)

  • IHC/IF: Include appropriate positive control tissues (e.g., tissues known to express pY33-WWOX)

  • ELISA: Generate standard curves with recombinant phosphorylated protein

  • Compare results across multiple applications when possible

• Technical reproducibility:

  • Test multiple antibody lots if available

  • Document specific experimental conditions that affect detection

  • Establish internal positive controls for ongoing experiments

How can researchers design experiments to investigate the functional significance of WWOX Tyr33 phosphorylation?

To elucidate the functional significance of WWOX Tyr33 phosphorylation, researchers can employ these experimental approaches:

• Phosphorylation site mutations:

  • Create expression constructs for:

    • Wild-type WWOX

    • Y33F mutant (prevents phosphorylation)

    • Y33E/D mutant (phosphomimetic)

  • Compare functional outcomes in transfected cells (apoptosis rates, protein interactions, cellular localization)

• Regulated phosphorylation/dephosphorylation:

  • Identify stimuli that induce Tyr33 phosphorylation (e.g., UV irradiation, TNF, anisomycin)

  • Use tyrosine kinase inhibitors to block phosphorylation (e.g., Src inhibitors)

  • Employ phosphatase inhibitors to maintain phosphorylation status

• Protein interaction studies:

  • Compare binding partners of wild-type vs. phospho-mutant WWOX using:

    • Co-immunoprecipitation followed by Western blot or mass spectrometry

    • Proximity ligation assays to visualize interactions in situ

    • Bimolecular fluorescence complementation (BiFC)

  • Focus on known interactors like p53, JNK1, ERK, and transcription factors

• Subcellular localization analysis:

  • Track localization of wild-type vs. phospho-mutant WWOX under various conditions

  • Use confocal microscopy with organelle markers (nucleus, mitochondria, Golgi, lysosomes)

  • Analyze nuclear translocation following stress stimuli

• Functional readouts:

  • Apoptosis assays (Annexin V, TUNEL, caspase activation)

  • Cell cycle analysis

  • Transcriptional reporter assays for WWOX-regulated pathways

  • Migration and invasion assays for cancer-related studies

  • Tau phosphorylation status for neurodegeneration models

• Disease model interventions:

  • Test effects of modulating Tyr33 phosphorylation in disease models

  • For cancer: Evaluate tumor growth, metastasis, and microenvironment interactions

  • For neurodegeneration: Assess protein aggregation, neuronal survival, and behavioral outcomes

What are the best practices for quantifying changes in WWOX Tyr33 phosphorylation levels?

Accurate quantification of WWOX Tyr33 phosphorylation is essential for meaningful comparisons across experimental conditions:

• Normalization strategies:

  • Normalize phosphorylated WWOX to total WWOX protein (requires separate detection)

  • Use dual staining techniques when possible (phospho-specific + total protein antibodies)

  • Include invariant loading controls (β-actin, GAPDH) for total protein normalization

• Quantitative Western blotting:

  • Use digital imaging systems rather than film for better dynamic range

  • Establish linear range of detection for each antibody

  • Run standard curves with known quantities of recombinant phosphorylated protein

  • Include biological replicates (n≥3) and technical replicates

  • Report normalized band intensities with appropriate statistical analysis

• Quantitative microscopy:

  • Use consistent exposure settings across all samples

  • Employ automated analysis algorithms to reduce bias

  • Measure signal intensity, area, and subcellular distribution

  • Include sufficient cell numbers for statistical significance

  • Normalize phospho-signal to total WWOX signal in dual-labeled samples

• ELISA-based quantification:

  • Cell-based ELISA kits can measure relative amounts of phosphorylated WWOX in cultured cells without lysate preparation

  • Standard sandwich ELISA can be used for tissue/cell lysates

  • Include standard curves and appropriate controls

  • Account for matrix effects in complex samples

• Mass spectrometry approaches:

  • Phosphopeptide enrichment techniques (TiO₂, IMAC)

  • Targeted MS approaches like multiple reaction monitoring (MRM)

  • SILAC or TMT labeling for relative quantification

  • Absolute quantification using isotope-labeled peptide standards

• Flow cytometry:

  • For single-cell resolution of phosphorylation status

  • Requires validated phospho-specific antibodies compatible with flow cytometry

  • Particularly useful for heterogeneous cell populations

• Temporal considerations:

  • Design time course experiments to capture dynamic phosphorylation changes

  • Consider rapid fixation methods to preserve phosphorylation status

  • Document time from stimulation to sample processing

How can Phospho-WWOX (Tyr33) antibodies be used to investigate disease mechanisms?

Phospho-WWOX (Tyr33) antibodies offer powerful tools for dissecting disease mechanisms across multiple pathologies:

• Cancer research applications:

  • Monitor pY33-WWOX status during cancer progression

  • Track the pY33-to-pS14 transition as a potential biomarker

  • Investigate differences between WWOX-positive vs. WWOX-negative cancer cells

  • Study how WWOX phosphorylation affects cancer cell behavior in the microenvironment

  • Evaluate therapeutic responses that might restore pY33-WWOX function

• Neurodegenerative disease investigations:

  • Analyze pY33-WWOX levels in Alzheimer's disease models and patient samples

  • Examine how pY33-WWOX interacts with tau-phosphorylating enzymes

  • Investigate the role of WWOX phosphorylation in protein aggregation cascades

  • Explore pY33-WWOX as a potential neuroprotective factor

• Inflammation and immune response studies:

  • Examine pY33-WWOX status in sepsis models and inflammatory conditions

  • Investigate WWOX phosphorylation in immune cell function

  • Study the relationship between inflammatory cytokines and WWOX phosphorylation

• Drug development applications:

  • Screen compounds that stabilize pY33-WWOX or prevent its loss

  • Evaluate drugs that inhibit the pY33-to-pS14 transition

  • Develop therapeutic approaches targeting WWOX phosphorylation pathways

• Biomarker development:

  • Validate pY33-WWOX as a diagnostic or prognostic biomarker

  • Develop assays for detecting pY33-WWOX in clinical samples

  • Correlate pY33-WWOX levels with disease progression and treatment outcomes

What emerging techniques are advancing the study of WWOX phosphorylation dynamics?

The field of WWOX phosphorylation research is benefiting from several cutting-edge technologies:

• Live-cell phosphorylation sensors:

  • FRET-based biosensors for real-time monitoring of WWOX phosphorylation

  • Genetically encoded indicators that change fluorescence upon phosphorylation

  • These approaches allow dynamic visualization of phosphorylation events in living cells

• Single-cell phosphoproteomics:

  • Mass cytometry (CyTOF) with phospho-specific antibodies

  • Single-cell Western blotting

  • These techniques reveal heterogeneity in WWOX phosphorylation across cell populations

• Spatial phosphoproteomics:

  • Imaging mass spectrometry to map phosphorylation patterns in tissue sections

  • Highly multiplexed immunofluorescence (e.g., CODEX, MIBI)

  • These methods preserve spatial context of phosphorylation events

• CRISPR-based approaches:

  • Base editing to introduce specific phosphorylation site mutations

  • CRISPR activation/interference to modulate kinases/phosphatases regulating WWOX

  • These genetic tools enable precise manipulation of phosphorylation pathways

• Computational modeling:

  • Systems biology approaches to model WWOX phosphorylation networks

  • Machine learning to predict phosphorylation outcomes from multi-omics data

  • In silico screening of compounds affecting WWOX phosphorylation

• Organoid and patient-derived xenograft models:

  • More physiologically relevant systems for studying WWOX phosphorylation

  • Disease-specific contexts for evaluating phosphorylation dynamics

  • These models bridge the gap between cell culture and in vivo studies

How might targeting WWOX phosphorylation impact future therapeutic strategies?

Modulating WWOX phosphorylation represents a promising avenue for therapeutic development:

• Cancer therapeutics:

  • Strategies to maintain or restore pY33-WWOX could enhance its tumor suppressor function

  • Inhibiting the pY33-to-pS14 transition might prevent cancer progression

  • Combining WWOX-targeted approaches with existing therapies could improve outcomes

  • According to research, metastatic WWOX-negative cancer cells exhibit specific behaviors that could be targeted therapeutically

• Neurodegeneration interventions:

  • Preserving pY33-WWOX might protect against tau hyperphosphorylation and aggregation

  • Reducing pS14-WWOX formation could potentially slow disease progression

  • Zfra peptide has shown promise in mitigating Alzheimer's disease progression by suppressing pS14-WWOX

• Inflammatory conditions:

  • Modulating WWOX phosphorylation could affect inflammatory signaling pathways

  • Targeting the WWOX-NF-κB relationship might provide anti-inflammatory benefits

  • Restoring normal pY33-WWOX levels could potentially ameliorate sepsis-associated cognitive effects

• Dual targeting approaches:

  • Simultaneously targeting kinases that phosphorylate WWOX and downstream effectors

  • Combining WWOX phosphorylation modulators with pathway-specific inhibitors

  • These approaches might provide synergistic therapeutic effects

• Personalized medicine implications:

  • WWOX phosphorylation status could serve as a biomarker for patient stratification

  • Therapies could be tailored based on individual WWOX phosphorylation profiles

  • Cell-Based ELISA kits offer tools for assessing WWOX phosphorylation in patient samples

• Delivery challenges and solutions:

  • Developing targeted delivery systems for WWOX-modulating compounds

  • Creating cell-penetrating peptides that affect WWOX phosphorylation

  • These approaches could improve therapeutic efficacy while reducing off-target effects